pharmaceuticals





 

Four advanced product opportunities with significant peak sales potential have been identified. Some of these compounds have been in-licensed by Fovea from major players of the industry: CombinatoRx (NASDAQ: CRXX), Dyax (NASDAQ: DYAX), and Novartis (NYSE: NVS).

Our pipeline is organized to address several amongst the most important indications in ophthalmology:

Chronic Allergic Conjunctivitis

  • FOV1101/ Prednisporin™ is a product developed for the treatment of allergic conjunctivitis. It is a proprietary formulation of a topical combination of prednisolone and cyclosporine A, each at a lower than usual clinical dosage to maximize safety profile while maintaining clinical efficacy. Fovea has acquired exclusive worldwide rights to this product from CombinatoRx. Positive phase 2 data have been obtained Q2 2009. Further development is ongoing.

Macular Edema

  • FOV2302 is the ophthalmic application of DX-88, a proprietary plasma kallikrein-kinin inhibitor currently awaiting FDA approval for systemic treatment of hereditary angioedema. Fovea has acquired European rights to this product from Dyax. FOV2302 is currently being evaluated in phase 2 clinical trial for use as an intravitreal formulation of DX-88 in the treatment of Retinal Vein Occlusion (RVO)-induced acute macular edema.
  • FOV2304 is a product developed for the treatment of Diabetic Macular Edema (DME). This New Chemical Entity which has the capacity to be active by topical (eye drops) administration will be administered in human in November 2009. The product is expected to enter into clinical development in 2009.

Retinitis Pigmentosa

  • FOV2501 is an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with potential extension to dry Age related Macular Degeneration (AMD). Pr. José-Alain Sahel and his team at INSERM identified RdCVF by using the same technology platform that was subsequently duplicated at Fovea. This protein has demonstrated efficacy in two relevant animal model. Fovea has acquired exclusive worldwide rights to RdCVF from Novartis with a call back option to Novartis at the end of Phase II. The product is expected to enter into clinical development in 2010.
Back to top